EGFR+ Lung Cancer | Clinical

D-0316 Shows Clinically Meaningful Improvement in Patients with T790M+ and EGFR+ NSCLC

April 12, 2021

More than half of patients with T790M-positive non-small cell lung cancer had a response to the third generation EGFR TKI D-0316 in a phase 2 study.

Filling in the Treatment Gap for Patients With EGFR+ NSCLC

April 09, 2021

Xiuning Le, MD, PhD, discusses the limited treatment options available for patients with non–small cell lung cancer and an EGFR exon 20 mutation.

Implementation of Earlier Diagnoses and Testing May Maximize Survival Outcomes for EGFR+ NSCLC

April 09, 2021

According to a retrospective analysis presented during the 2021 European Lung Cancer Congress, earlier diagnosis and biomarker testing should be more widely implemented to identify patients with EGFR-positive non–small lung cancer who may benefit for EGFR inhibition.

Afatinib Shows Encouraging Efficacy and Safety in Late Stage EGFR-Mutant NSCLC

April 08, 2021

Integrating afatinib into standard-of-care chemoradiation with or without surgery demonstrated encouraging efficacy, feasibility, and safety results in patients with stage III EGFR-mutation positive non–small cell lung cancer.

Neratinib Is Effective Against EGFR Exon 18 Mutations in NSCLC

April 06, 2021

Neratinib demonstrated single-agent efficacy with significant response and survival rates in tyrosine kinase inhibitor-refractory patients with non– small cell lung cancer whose tumors harbor EGFR exon 18 mutations.

Real-World Mobocertinib Data Lay Groundwork for Further EGFR+ NSCLC Research

March 13, 2021

Leora Horn, MD, discusses how real-world data of mobocertinib as treatment of refractory EGFR-positive non–small cell lung cancer and other real-world studies can impact the treatment paradigm.

Osimertinib Plus Gefitinib Feasible for First-Line Treatment of EGFR-Mutated

March 09, 2021

In an interview with Targeted Oncology, Julia K. Rotow, MD, a medical oncologist at the Dana-Farber Cancer institute, discuses the results of the study of gefitinib in combination with osimertinib as frontline treatment of patients with EGFR-mutated NSCLC.

Osimertinib Penetrates Blood-Brain Barrier and Decreases Metastasis in EGFR+ NSCLC

February 24, 2021

In with EGFR-mutant non–small cell lung cancer and brain metastases, oral osimertinib achieved rapid, high, and uniform brain exposure which was followed reduction in total brain metastases volume, according to results from the phase 1 ODIN-BM study.

NeoADAURA Trial Launches With Plans to Assess Neoadjuvant Osimertinib in Resectable EGFR+ NSCLC

February 18, 2021

n patients with resectable, stage II-IIIB non–small cell lung cancer whose tumors harbor EGFR mutations, neoadjuvant osimertinib will be administered as a single agent or in combination with platinum-based chemotherapy compared with chemotherapy alone in the NeoADAURA trial

EGFR/RET TKI Combination Active Against EGFR+ NSCLC With Acquired RET Fusion

February 04, 2021

The combination of osimertinib and selpercatinib was found to be an active regimen in patients with EGFR-positive non–small cell lung cancer with acquired RET fusions.